Cargando…
A lack of race and ethnicity data in the treatment of hereditary hemorrhagic telangiectasia: a systematic review of intravenous bevacizumab efficacy
BACKGROUND: For extreme hereditary hemorrhagic telangiectasia (HHT) disease, treatments such as intravenous bevacizumab are often utilized. However, whether its efficacy is similar across diverse races and ethnicities is unclear. METHODS: In this systematic review, we performed a search for English-...
Autores principales: | Galiatsatos, Panagis, Wilson, Cheri, O’Brien, Jaime, Gong, Anna J., Angiolillo, Dylan, Johnson, James, Myers, Carlie, Strout, Sara, Mathai, Stephen, Robinson, Gina, Rowan, Nicholas R., Weiss, Clifford R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195340/ https://www.ncbi.nlm.nih.gov/pubmed/35698080 http://dx.doi.org/10.1186/s13023-022-02371-0 |
Ejemplares similares
-
The Impact on COVID-19 by Intravenous Bevacizumab Used for Hereditary Hemorrhagic Telangiectasia: A Case Report
por: Fanning, Ryan Patrick, et al.
Publicado: (2022) -
Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia
por: Ou, George, et al.
Publicado: (2016) -
Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
por: Buscarini, Elisabetta, et al.
Publicado: (2019) -
Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab
por: Wee, Jee Wan, et al.
Publicado: (2014) -
Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab
por: Masood, Muaaz, et al.
Publicado: (2021)